Free Republic

The FDA has lifted a pause on the administration of a vaccine for the chikungunya virus, a mosquito-borne illness currently spreading from China. The Ixchiq single-dose vaccine was approved for adults 18 and up at risk of exposure to the virus in 2023 But administrations of the shot to adults aged 60 and older were paused in May of this year, triggered by reports of 17 serious side effects following vaccination, including two deaths. Most of the reported issues were neurological or cardiac, and all involved people over 60. An FDA spokesperson told DailyMail.com: ‘FDA has completed an updated benefit-risk...

The U.S. Food and Drug Administration (FDA) on Thursday announced its approval of Ixchiq, the first chikungunya vaccine. The vaccine, which is made by Valneva, is approved for anyone age 18 and older who has a risk of being exposed to the virus. The chikungunya virus is transmitted to people through bites from infected mosquitoes. "This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes," noted Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor. The FDA described chikungunya as an "emerging global...